Iterum Therapeutics will announce Q3 2025 financial results on November 14, 2025, with a conference call to follow.
Quiver AI Summary
Iterum Therapeutics plc announced that it will release its third quarter 2025 financial results on November 14, 2025, before U.S. market opening, followed by a conference call at 8:30 a.m. ET to discuss these results and provide a business update. The call can be accessed via a designated phone number and Access Code or by pre-registering online. Iterum is dedicated to developing next-generation oral and IV antibiotics to tackle multi-drug resistant infections, particularly with its leading compound, sulopenem, which has shown effectiveness against various resistant bacteria. The company has received FDA approval for its oral formulation, ORLYNVAH™, for treating specific urinary tract infections and has secured important designations to expedite its development.
Potential Positives
- Iterum Therapeutics is set to release its third quarter 2025 financial results, indicating transparency and engagement with investors.
- The company’s first compound, sulopenem, has received NDA approval from the U.S. FDA for the treatment of uncomplicated urinary tract infections, highlighting its successful entry into the market.
- Sulopenem has been recognized with Qualified Infectious Disease Product (QIDP) and Fast Track designations, which may enhance its development and commercialization prospects.
Potential Negatives
- Announcement of financial results before market open may indicate potential concerns about performance if results are not favorable.
- The focus on antibiotic treatment for multi-drug resistant pathogens suggests a high level of competition and regulatory scrutiny, indicating challenges in achieving market success.
- Dependence on the reception of sulopenem, which has been approved for limited use, raises questions about the company's ability to broaden its market presence and secure long-term profitability.
FAQ
When will Iterum Therapeutics release its Q3 2025 financial results?
Iterum Therapeutics will release its third quarter 2025 financial results on November 14, 2025, before the U.S. markets open.
How can I access the conference call for the financial results?
You can access the conference call by dialing 833-470-1428 for domestic calls or 404-975-4839 for international calls.
What is sulopenem developed by Iterum Therapeutics?
Sulopenem is a novel penem anti-infective compound effective against multi-drug resistant bacteria, available in oral and IV formulations.
What designations has sulopenem received from the FDA?
Sulopenem has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for several indications.
Where can I find more information about Iterum Therapeutics?
More information about Iterum Therapeutics can be found on their official website at www.iterumtx.com.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ITRM Insider Trading Activity
$ITRM insiders have traded $ITRM stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $ITRM stock by insiders over the last 6 months:
- MICHAEL W. DUNNE purchased 15,000 shares for an estimated $10,854
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ITRM Hedge Fund Activity
We have seen 12 institutional investors add shares of $ITRM stock to their portfolio, and 3 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SQUAREPOINT OPS LLC added 456,861 shares (+inf%) to their portfolio in Q2 2025, for an estimated $454,576
- SABBY MANAGEMENT, LLC added 430,761 shares (+inf%) to their portfolio in Q2 2025, for an estimated $428,607
- RENAISSANCE TECHNOLOGIES LLC added 231,000 shares (+95.9%) to their portfolio in Q2 2025, for an estimated $229,845
- JANE STREET GROUP, LLC added 92,943 shares (+inf%) to their portfolio in Q2 2025, for an estimated $92,478
- ONEDIGITAL INVESTMENT ADVISORS LLC added 60,000 shares (+59.4%) to their portfolio in Q2 2025, for an estimated $59,700
- KRILOGY FINANCIAL LLC added 40,000 shares (+inf%) to their portfolio in Q3 2025, for an estimated $26,800
- SG AMERICAS SECURITIES, LLC added 16,820 shares (+inf%) to their portfolio in Q3 2025, for an estimated $11,269
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
DUBLIN, Ireland and CHICAGO, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its third quarter 2025 financial results before the open of the U.S. financial markets on Friday, November 14, 2025. Management will host a conference call at 8:30 a.m. ET that day to discuss the Company’s financial results and provide an update on its business.
To access the call please dial 833-470-1428 (domestic) or 404-975-4839 (international) and refer to Access Code 459214. To pre-register for this call, please go to the following link: https://events.q4inc.com/attendee/334189282 . The audio webcast can be accessed under “Financials & Filings” in the Investors section of the Company’s website at www.iterumtx.com following the call.
About Iterum Therapeutics plc
Iterum Therapeutics plc is focused on delivering differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum is advancing the development of its first compound, sulopenem, a novel penem anti-infective compound, with an oral formulation and IV formulation. Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. Iterum has received approval of its NDA for ORLYNVAH™ (oral sulopenem) for the treatment of uncomplicated urinary tract infections caused by the designated microorganisms Escherichia coli , Klebsiella pneumoniae , or Proteus mirabilis in adult women with limited or no alternative oral antibacterial treatment options by the U.S. Food and Drug Administration and has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications. For more information, please visit www.iterumtx.com .
Investor Contact:
Judy Matthews
Chief Financial Officer
312-778-6073
[email protected]
